In summary, claudin dysregulation in endometrial cancer is tied to subtype, invasion, and outcome: high CLDN6/CLDN9 confers poor survival (66, 152), and may also reflect an immune-cold microenvironment analogous to ovarian tumors. Here, CLDN6 is linked to endometrial cancer.